Quotient Sciences’ focus is on delivering the most appropriate formulations to expedite your clinical program, through dosing within our own Phase I clinical facilities or at an external site. We work with you to support rapid progression to your first-in-human evaluation where required, ensuring that your ultimate drug product presentation goals can be seamlessly transitioned following confirmation of molecule safety and tolerability. Our formulators’ experience is built on years of work integrating formulation development and clinical evaluation. As a result, our development is based on an understanding of the intended indication including drug products designed for chronic dosing or for pediatric populations.
Our breadth of formulations developed for first-in-human studies includes:
- APIs in a bottle or capsule
- Solutions
- Suspensions
- Tablets
- Capsules
- Parenterals
- Solubility-enhanced dosage forms
First-in-human
Go further with Quotient Sciences
-
Fact Sheet
First-in-Human to Proof-of-Concept
Our Translational Pharmaceutics approach enables First-in-Human studies by re-engineering the transition of your drug molecule into clinical development and shortening the timeline to Proof-of-Concept.
-
Fact Sheet
Global formulation development and manufacturing capabilities
We provide full service support for small molecule non-sterile programs, from dosage formulation development through to GMP clinical trial manufacturing and commercial drug product supply.
-
Webinar
Pharmaceutical spray drying to overcome poor drug solubility
Overcoming poor drug solubility is a common and challenging task facing the formulation scientist today.
-
Webinar
How to Reduce the Time and Cost for Optimizing Drug Product Formulations
Join industry experts John McDermott, Executive Director of Drug Product Optimization, and Kieran Crowley, Senior Scientific Director, both from Quotient Scienbces, as they outline studies and metrics in drug delivery and drug product optimization.